HCP Exclusive Products
SiPore® Capsules
Maintenance metabolic support for long-term stability
Capsules | Supplement | Up to 2 times daily
Designed for sustainable meal-level modulation and long-term metabolic balance.
Best suited for:
- Everyday post-meal glucose support
- Long-term metabolic well-being and healthy ageing
- Maintenance phases after intensive protocols
- Patients preferring capsule format
Daily steadiness. Appetite regulation. Long-term use.
SiPore® Liquid
High-intensity meal-level intervention for structured protocols
Liquid sachets | Medical Food | Up to 3 times daily
Designed for higher per-meal modulation in defined clinical settings.
Best suited for patients with nutritional management needs during:
- Weight‑loss phases with lean‑mass preservation
- A1C reduction strategies
- Post‑GLP‑1 taper support
- Higher‑appetite and central adiposity management
Stronger per-meal modulation. Structured protocol use.
SiPore® Early Access Clinical Pilot
Bring Meal-Level Metabolic Support Into Your Practice
Apply for early access to SiPore® Liquid, a gut-local, non-systemic approach designed to support steadier post-meal metabolic patterns, appetite stability, and structured metabolic health workflows.
Participating practices receive:
- Pilot product access for real-world implementation
- Practitioner Hub onboarding and protocol resources
- Structured support for weight management and metabolic health workflows
- Optional CGM/TIR workflow integration
HCP only • Limited onboarding • Pilot product included
Metabolic Stress: The Upstream Driver of Metabolic Disease
Metabolic syndrome is the diagnosis. Metabolic stress is the mechanism.
In modern food systems characterized by fast energy, high reward, and constant availability, repeated high-load meals drive cumulative metabolic stress. Over time, this contributes to obesity, type 2 diabetes, and cardiometabolic disease.
Metabolic Health Remains Unsolved
Lifestyle Adaptation
Effective in principle, difficult to sustain in modern food environments. Requires high adherence and long-term behavioral discipline.
Systemic Interventions
Clinically appropriate for defined populations. Systemic by design and typically ongoing.
The Third Strategy: Meal-Level Input Modulation
SIGRID’s approach represents a third strategy, powered by patented SiPore® technology. Our products are designed to be taken with everyday meals.
They work locally in the gut to support a reduced digestive impact from carbohydrates and fats during digestion.
Less impact per meal. Metabolic stability over time.
SiPore®: Gut-Local Modulation of Metabolic Load
SiPore® is a patented, precision-engineered silica material with a precisely controlled pore structure. It is designed to function locally in the small intestine during digestion to reduce per-meal metabolic load.
Non-systemic. Not absorbed.
1) Enzyme Entrapment in the Small Intestine
During digestion, SiPore® particles mix with food and digestive enzymes. The engineered pores entrap a portion of alpha-amylase and lipase.
2) Reduced Carbohydrate and Fat Breakdown
Reduced enzyme activity slows the breakdown of carbohydrates and fats.
3) More Gradual Energy Absorption
Slower digestion results in a more gradual release of energy into the bloodstream.
4) Lower Post-Meal Metabolic Load
Each meal delivers a lower metabolic impact, supporting steadier post-meal physiology.
Mechanism-Led. Clinically Evaluated.
SiPore® technology has been evaluated across pre-clinical and clinical studies.
Primary Protocols
Structured Use Frameworks for Meal-Level Metabolic Modulation
SIGRID’s products, powered by patented SiPore® technology, can be integrated into structured care frameworks to support weight management, post-meal glucose balance, appetite regulation, and metabolic stability.
Frequently Asked Questions
No. SiPore® acts locally in the small intestine during digestion and is not absorbed into the bloodstream. It passes through the gastrointestinal tract.
SiPore® is a patented, precision-engineered silica material with a precisely defined pore structure designed for digestive enzyme entrapment.
Unlike dietary fiber, which primarily adds bulk or influences fermentation, SiPore® is engineered to physically interact with digestive enzymes through a mechanical mode of action.
SiPore® is designed to entrap a portion of alpha-amylase and lipase in the small intestine, reducing the rate of carbohydrate and fat breakdown.
No. SiPore® supports meal-level modulation through digestive enzyme entrapment.
It slows the breakdown of carbohydrates and fats but does not fully inhibit nutrient digestion or absorption.
Yes. SiPore® acts locally in the gut and does not have systemic exposure. It is designed to complement, not replace, pharmacologic therapies.
Yes. Structured meal‑level modulation may support balanced appetite dynamics and post‑meal glucose patterns during GLP‑1 transition phases.
By entrapping a portion of alpha-amylase and lipase in the small intestine and reducing the rate of carbohydrate and fat breakdown, SiPore® provides a non-systemic tool to help manage the metabolic impact of individual meals as patients move toward long-term lifestyle-based maintenance.
SiPore® technology has been evaluated in multiple clinical studies and demonstrated a strong safety and tolerability profile.
Yes. It is designed to complement diet and behavioral strategies by reducing the metabolic impact of individual meals.